Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.5.0.2
Segments
9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
SEGMENTS
SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of Bio-Reference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended September 30,
 
For the nine months ended September 30,
(In thousands)
2016
 
2015
 
2016
 
2015
Revenue from services:
 
 
 
 
 
 
 
Pharmaceutical
$

 
$
160

 
$

 
$
192

Diagnostics
259,025

 
103,739

 
777,559

 
107,597

Corporate

 
20

 

 
140

 
$
259,025

 
$
103,919

 
$
777,559

 
$
107,929

Product revenues:
 
 
 
 
 
 
 
Pharmaceutical
$
20,569

 
$
20,765

 
$
63,275

 
$
59,066

Diagnostics

 

 

 

Corporate

 

 

 

 
$
20,569

 
$
20,765

 
$
63,275

 
$
59,066

Revenue from transfer of intellectual property:
 
 
 
 
 
 
 
Pharmaceutical
$
18,441

 
$
18,350

 
$
105,338

 
$
48,552

Diagnostics

 

 

 

Corporate

 

 

 

 
$
18,441

 
$
18,350

 
$
105,338

 
$
48,552

Operating income (loss):
 
 
 
 
 
 
 
Pharmaceutical
$
(18,593
)
 
$
5,300

 
$
15,422

 
$
(36,861
)
Diagnostics
3,098

 
(1,961
)
 
11,117

 
(17,961
)
Corporate
(8,128
)
 
(11,562
)
 
(49,414
)
 
(34,444
)
Less: Operating loss attributable to noncontrolling interests

 

 

 
(1,281
)
 
$
(23,623
)
 
$
(8,223
)
 
$
(22,875
)
 
$
(90,547
)
Depreciation and amortization:
 
 
 
 
 
 
 
Pharmaceutical
$
6,994

 
$
2,775

 
$
12,841

 
$
6,902

Diagnostics
18,818

 
9,602

 
59,711

 
13,103

Corporate
20

 
22

 
60

 
68

 
$
25,832

 
$
12,399

 
$
72,612

 
$
20,073

Net income (loss) from investment in investees:
 
 
 
 
 
 
 
Pharmaceutical
$
399

 
$
(3,502
)
 
$
(5,643
)
 
$
(6,067
)
Diagnostics
(1,213
)
 

 
496

 

Corporate

 

 

 

 
$
(814
)
 
$
(3,502
)
 
$
(5,147
)
 
$
(6,067
)
Revenues:
 
 
 
 
 
 
 
United States
$
259,221

 
$
104,358

 
$
777,703

 
$
109,359

Ireland
20,594

 
22,308

 
114,526

 
53,807

Chile
9,936

 
7,779

 
26,516

 
22,929

Spain
3,910

 
3,447

 
12,257

 
12,303

Israel
3,699

 
4,154

 
12,862

 
14,309

Mexico
675

 
988

 
2,308

 
2,840

 
$
298,035

 
$
143,034

 
$
946,172

 
$
215,547


(In thousands)
September 30,
2016
 
December 31,
2015
Assets:
 
 
 
Pharmaceutical
$
1,318,377

 
$
1,234,752

Diagnostics
1,412,726

 
1,421,034

Corporate
68,924

 
143,402

 
$
2,800,027

 
$
2,799,188

Goodwill:

 

Pharmaceutical
$
257,570

 
$
251,225

Diagnostics
442,956

 
492,123

Corporate

 

 
$
700,526

 
$
743,348



During the three and nine months ended September 30, 2015, revenue recognized under the Pfizer Transaction represented 12% and 22%, respectively, of our total consolidated revenue. Refer to Note 12. No customer represented more than 10% of our total consolidated revenue during the three and nine months ended September 30, 2016. As of September 30, 2016 , no customer represented more than 10% of our accounts receivable balance. As of December 31, 2015, one customer represented more than 10% of our accounts receivable balance.